Shire clinches Baxalta in deal worth US$32b
Print Edition
DRUGMAKER Shire Plc clinched its six-month pursuit of Baxalta International Inc yesterday with an agreed US$32 billion cash and stock offer, catapulting it to a leading position in treating rare diseases.
The London-listed group, which first approached the US firm with an all-stock offer in July, won over the maker of treatments for rare blood conditions, cancers and immune system disorders after adding a cash sweetener.
Shareholders will receive US$18 in cash and 0.1482 Shire American depositary shares per Baxalta share, implying a total value of US$45.57 per share based on last Friday’s prices.
The deal marks a strong start to mergers and acquisitions in health care in 2016 after the sector saw its biggest deal-making streak in history last year, with global deals totaling US$673 billion, according to Thomson Reuters data.
Illinois-based Baxalta, which was spun off last year from Baxter International, rejected Shire’s previous US$30 billion all-stock offer in August, arguing it sharply undervalued the company.
But Shire CEO Flemming Ornskov relentlessly pursued Baxalta, seeking to pressure it into agreeing to a deal by meeting with Baxalta’s major shareholders over a period of months.
That enabled it to sidestep a hostile deal in which it would have faced takeover defenses including a “poison pill” that stopped unwanted suitors from buying more than 10 percent of the company and a hard-to-replace board.
Ornskov added cash and raised the offer price to offset the loss of a tax benefit shareholders would have received if the company remained independent.
Together, the two companies said they expected to deliver double-digit sales growth with over US$20 billion in annual revenues by 2020.
The offer price compares with Baxalta’s price of US$32.58 on August 3, before Shire went public with its interest in the company.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
